675576-97-3

Basic information

• Product Name: Nutlin-3b
• Synonyms: Nutlin-3b;4-[[(4R,5S)-4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone;2-Piperazinone, 4-[[(4R,5S)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-;4-[[(4R,5S)-4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone Nutlin 3b;4-[[(4R,5S)-4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imid
• CAS NO: 675576-97-3
• Molecular Formula: C30H30Cl2N4O4
• Molecular Weight: 581.4896
• Product Categories: Inhibitors
• Mol File: 675576-97-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.36
• Solubility: insoluble in H2O; ≥55.5 mg/mL in EtOH; ≥57.25 mg/mL in DMSO
• PKA: 14.35±0.20(Predicted)
• CAS DataBase Reference: Nutlin-3b(CAS DataBase Reference)
• NIST Chemistry Reference: Nutlin-3b(675576-97-3)
• EPA Substance Registry System: Nutlin-3b(675576-97-3)

Safety Data

• Hazardous Substances Data: 675576-97-3(Hazardous Substances Data)

Usage

Description

Nutlin-3b, also known as (+)-Nutlin-3, is a small molecule MDM2 antagonist that is the less active enantiomer of the p53-Mdm2 protein-protein interaction inhibitor (–)-nutlin-3. It inhibits the interaction between p53 and Mdm2, although with a significantly lower potency compared to its more active counterpart. Nutlin-3b has been utilized as a negative control for the p53-modulating activity of (–)-nutlin-3 in cancer cells.

Uses

Used in Pharmaceutical Research:
Nutlin-3b is used as a negative control agent for [the study of p53-modulating activity] in cancer cells. This application is due to its lower potency in inhibiting the interaction between p53 and Mdm2 compared to (–)-nutlin-3, making it a valuable tool for understanding the effects of the more active compound on cancer cell behavior.
Used in Cancer Cell Studies:
Nutlin-3b is used as a comparative compound for [investigating the effects of (–)-nutlin-3 on cancer cells]. The reason for this application is its contrasting activity levels with (–)-nutlin-3, which allows researchers to better comprehend the mechanisms of action and potential therapeutic benefits of the more potent compound in the context of cancer treatment.

references

[1] tovar c, rosinski j, filipovic z, higgins b, kolinsky k, hilton h, zhao x, vu bt, qing w, packman k, myklebost o, heimbrook dc, vassilev lt. small-molecule mdm2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. proc natl acad sci u s a. 2006 feb 7;103(6):1888-93.[2] cao c, shinohara et, subhawong tk, geng l, kim kw, albert jm, hallahan de, lu b. radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2. mol cancer ther. 2006 feb;5(2):411-7.